Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.
Adolescent
Adult
Aged
Aged, 80 and over
COVID-19
/ epidemiology
COVID-19 Serological Testing
Cancer Care Facilities
Carrier State
/ epidemiology
Child
Child, Preschool
Female
France
/ epidemiology
Health Personnel
/ statistics & numerical data
Humans
Male
Middle Aged
Personnel, Hospital
/ statistics & numerical data
SARS-CoV-2
Seroepidemiologic Studies
Young Adult
Antibody
COVID-19
Cancer center
Cancer patients
Healthcare workers
SARS-COV-2
Serodiagnosis
Serology
Seroprevalence
Staff
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
12
01
2021
revised:
12
02
2021
accepted:
22
02
2021
pubmed:
30
3
2021
medline:
8
5
2021
entrez:
29
3
2021
Statut:
ppublish
Résumé
In view of the potential gravity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection for patients with cancer, epidemiological data are vital to assess virus circulation among patients and staff of cancer centres. We performed a prospective study to investigate seroprevalence of SARS-CoV-2 antibodies among staff and patients with cancer at a large cancer centre, at the end of the period of first national lockdown in France and to determine factors associated with the risk of SARS-CoV-2 infection. After the first lockdown, all medical and non-medical staff, as well as all patients attending the medical oncology department were invited to undergo serological testing for SARS-CoV-2 between 11 May and 30 June 2020. All participants were also invited to complete a questionnaire collecting data about their living and working conditions, and for patients, medical management during lockdown. A total of 1,674 subjects (663 staff members, 1011 patients) were included. Seroprevalence was low in both staff (1.8%) and patients (1.7%), despite more features of high risk for severe forms among patients. None of the risk factors tested in our analysis (working or living conditions, comorbidities, management characteristics during lockdown) was found to be statistically associated with seroprevalence in either staff or patients. There was no significant difference in the proportion of symptomatic and asymptomatic subjects between staff and patients. Only fever, loss of smell, and loss of taste were significantly more frequent among seropositive patients, in both staff and patients. We report very low seroprevalence of antibodies against SARS-CoV-2 in the staff (caregiving and non-caregiving) and patients of a large cancer care centre in which strict hygiene, personal protection, and social distancing measures were implemented.
Sections du résumé
BACKGROUND
In view of the potential gravity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection for patients with cancer, epidemiological data are vital to assess virus circulation among patients and staff of cancer centres. We performed a prospective study to investigate seroprevalence of SARS-CoV-2 antibodies among staff and patients with cancer at a large cancer centre, at the end of the period of first national lockdown in France and to determine factors associated with the risk of SARS-CoV-2 infection.
METHODS
After the first lockdown, all medical and non-medical staff, as well as all patients attending the medical oncology department were invited to undergo serological testing for SARS-CoV-2 between 11 May and 30 June 2020. All participants were also invited to complete a questionnaire collecting data about their living and working conditions, and for patients, medical management during lockdown.
FINDINGS
A total of 1,674 subjects (663 staff members, 1011 patients) were included. Seroprevalence was low in both staff (1.8%) and patients (1.7%), despite more features of high risk for severe forms among patients. None of the risk factors tested in our analysis (working or living conditions, comorbidities, management characteristics during lockdown) was found to be statistically associated with seroprevalence in either staff or patients. There was no significant difference in the proportion of symptomatic and asymptomatic subjects between staff and patients. Only fever, loss of smell, and loss of taste were significantly more frequent among seropositive patients, in both staff and patients.
INTERPRETATION
We report very low seroprevalence of antibodies against SARS-CoV-2 in the staff (caregiving and non-caregiving) and patients of a large cancer care centre in which strict hygiene, personal protection, and social distancing measures were implemented.
Identifiants
pubmed: 33780664
pii: S0959-8049(21)00124-6
doi: 10.1016/j.ejca.2021.02.027
pmc: PMC7914029
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-370Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.
Références
Lancet Infect Dis. 2020 Dec;20(12):1401-1408
pubmed: 32758438
Ann Oncol. 2020 Aug;31(8):1087-1088
pubmed: 32360743
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Lancet Infect Dis. 2020 Sep;20(9):996-998
pubmed: 32539989
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
J Med Virol. 2020 Oct;92(10):1795-1796
pubmed: 32311142
ESMO Open. 2020 Sep;5(5):e000889
pubmed: 32878898
Eur J Cancer. 2020 Nov;139:181-187
pubmed: 33035991
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Ann Oncol. 2021 Jan;32(1):113-119
pubmed: 33098994
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613
Oncologist. 2020 Jun;25(6):e936-e945
pubmed: 32243668
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Natl Compr Canc Netw. 2020 Mar 20;:1-4
pubmed: 32197238
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Eur J Cancer. 2020 Aug;135:251-259
pubmed: 32540204
Front Public Health. 2020 Jun 05;8:267
pubmed: 32582617
Elife. 2020 Aug 21;9:
pubmed: 32820721
J Clin Oncol. 2020 Oct 20;38(30):3547-3554
pubmed: 32795227
N Engl J Med. 2020 Oct 29;383(18):1724-1734
pubmed: 32871063
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Nat Commun. 2020 Oct 8;11(1):5064
pubmed: 33033249
Eur J Cancer. 2020 Dec;141:62-81
pubmed: 33129039
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Ann Oncol. 2020 Oct;31(10):1420-1422
pubmed: 32710929
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
Am J Otolaryngol. 2020 Sep - Oct;41(5):102581
pubmed: 32563019
Ann Intern Med. 2021 Feb;174(2):286-287
pubmed: 33587872
Clin Infect Dis. 2021 May 4;72(9):1645-1648
pubmed: 32628750
Crit Rev Oncol Hematol. 2020 Jun;150:102972
pubmed: 32344317
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet Oncol. 2020 May;21(5):629-630
pubmed: 32247319
Eur J Cancer. 2020 Dec;141:171-184
pubmed: 33161241
JNCI Cancer Spectr. 2021 Jan 06;5(1):pkaa090
pubmed: 33604509
Nat Med. 2020 Aug;26(8):1171-1172
pubmed: 32719488